Alan S. Wolk, MBA
Chief Financial Officer & Chief Operating Officer
Daniele De Luca, MD, PhD
A. Béclère Medical Center
University of Paris-Saclay
Judy Aschner, MD
A. Béclère Medical Center
University of Paris-Saclay
Richard Parad, MD, MPH
Brigham & Women’s Hospital
Harvard University
Jeff Whitsett, MD
Cincinnati Children’s Hospital Medical Center
Maximo Vento, MD, PhD
Instituto de Investigación Sanitaria La Fe
(Health Research Institute La Fe)
Asaf Danziger
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States. From 1998 to 2002, Danziger was Chief Executive Officer of Cybro Medical, a subsidiary of Imagyn Medical Technologies. Danziger holds a Bachelor’s of Science in material engineering from Ben Gurion University of the Negev, Israel.
John M. Rice, PhD
John Rice is Managing Director at CincyTech, LLC, a venture development company focusing on seed venture capital investment where he leads the life science practice, and a co-founder and former Managing Partner of Triathlon Medical Ventures, both based in Cincinnati. He has 30 years of venture investing and 13 years of research and R&D management experience in biomedical science. He has strong relationships in the scientific community from the 26 years he spent in biomedical research and R&D management at Battelle and Senmed.
Rice was a Managing Director of Senmed Medical Ventures from 1989 until 2003. Previously, Rice spent 13 years with Battelle Memorial Institute serving in various research projects, research management, and business development capacities. He has authored numerous scientific publications and holds patents in the fields of virology and immunology.
Rice earned his BS, MS and PhD degrees in Microbiology and Virology from The Ohio State University.
Doug Loftus, CFP
Doug Loftus is the co-founder and managing member of Wealth Dimensions Group. He has more than 25 years of experience delivering comprehensive financial and investment advice to high-net-worth individuals and families, family offices, and nonprofits.
Loftus is active in nonprofit organizations, having served as a board member and chairman of the National Tuberous Sclerosis Association, and is also an active fundraiser for Cincinnati Children’s Hospital Medical Center.
Loftus received his BA degree in mathematics and computer science and a certificate in economics from the University of Cincinnati.
Marc Salzberg, MD, Chairman, Chief Executive Officer & Chief Medical Officer
Marc Salzberg is the Chief Executive Officer, Chief Medical Officer, and Chairman of the Board at Airway Therapeutics. With over 30 years of experience in academic medicine and the pharmaceutical industry, Marc has a proven track record in managing drug development and clinical research. His expertise spans the clinical management of anticancer and antiviral drug development, including the market introduction of saquinavir and ganciclovir.
Marc’s career includes several years at Roche’s headquarters in Basel, Switzerland, and its Canada affiliate, where he contributed significantly to the company’s global operations. He also served as Head of Clinical Cancer Research at the University of Basel, co-founding and leading a clinical research network in Switzerland (CCRC). Throughout his career, Marc has been instrumental in the growth and successful acquisition of two contract research organizations, delivering substantial value to shareholders. He was the founder and President of Pharma Brains, a European boutique contract research organization (CRO), which was acquired by Medpace after 10 years of successful growth under his leadership. Following the acquisition, he served as Vice President of Medical Affairs at Medpace.
Marc holds a Medical Doctorate from the University of Basel, Switzerland. His clinical training includes pediatrics, neonatology, and oncology. He is board certified in pharmaceutical medicine.
Alan S. Wolk, Chief Financial Officer & Chief Operating Officer
Alan S. Wolk is the Chief Financial Officer and Chief Operating Officer and Board Member at Airway Therapeutics. He possesses 30 years of extensive experience in global business management and leadership, corporate strategy, financial operations, and organizational leadership, and has had a distinguished career at DuPont and Invista, a subsidiary of Koch Industries, fostering business growth and enhancing operational efficiency.
Mr. Wolk has held multiple senior executive roles, including President of the $2B+ Interiors division at both DuPont and Invista, as well as Chief Financial Officer for DuPont Nylon, a $6.5B business segment. In his leadership roles, Mr. Wolk has managed global businesses with manufacturing and operations across North America, China, and Europe. Earlier in his career, Mr. Wolk served as CFO of DuPont’s pharmaceutical and diagnostics businesses, where he was instrumental in driving the division’s expansion. He played a pivotal role in several strategic mergers, acquisitions, and divestitures, particularly in China and Germany. His key contributions include leading DuPont’s acquisition of ICI Textiles, the joint venture between DuPont Pharma and Merck, and the sale of DuPont’s Virology business to Ortho. Prior to joining Airway Therapeutics, he taught Finance at the University of Georgia’s Terry College of Business.
He holds a Bachelor of Business Administration (BBA) in Marketing and a Master of Business Administration (MBA) in Finance, both from The Fox School of Business at Temple University.